Zelnorm Pulled From Market

James Sabatini

Contributor

0 CommentsPrint ArticleSubscribe

Swiss pharmaceutical maker Novartis AG will stop selling a drug to relieve constipation after it was linked to higher chance of heart attack, stroke and worsening heart chest pain that can become a heart attack, U.S. government health officials said Friday. Novartis agreed to withdraw Zelnorm at the FDA's request

Zelnorm, also called tegaserod maleate, is a prescription medication approved for short-term treatment of women with irritable bowel syndrome with constipation and for patients younger than 65 with chronic constipation, the FDA said.